Literature DB >> 8077339

Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.

B J Gertz1, J S Barrett, R Eisenhandler, D A Krupa, J M Wittreich, J R Seibold, S H Schneider.   

Abstract

L-692,429, a substituted benzolactam, is a novel nonpeptide mimic of the GH secretagogue, GH-releasing peptide-6. The safety and GH secretory activity of L-692,429 (0.001-1.0 mg/kg, i.v.) were investigated in 24 healthy nonobese young (18-26 yr old) male volunteers who demonstrated a GH response of 7 micrograms/L or more after 1 microgram/kg, i.v. GH-releasing hormone [GH-releasing hormone-(1-29)NH2]. L-692,429 was administered as a 15-min iv infusion in an incremental dose, double blind, placebo-controlled, alternating panel fashion to 3 panels of 8 subjects each. Dose-dependent GH secretion was observed with a threshold dose of 0.05 mg/kg (4 of 6 subjects responded with peak GH > 7 micrograms/L), and 0.2 mg/kg produced a response in all 14 subjects tested (mean +/- SE peak GH, 41.0 +/- 6.3 micrograms/L). The maximum dose of 1.0 mg/kg L-692,429 resulted in a pronounced GH response (peak GH, 82.5 +/- 14.9 micrograms/L; n = 8). The GH peak was seen 30-45 min after initiation of the infusion. Small transient increases in cortical and PRL were observed (increases in cortical averaged 182.1 +/- 33.1 nmol/L and peak PRL was 21 +/- 2.6 micrograms/L after 1.0 mg/kg L-692,429, respectively), whereas no significant changes occurred in LH, FSH, TSH, insulin, or glucose concentrations. Plasma pharmacokinetic analysis revealed dose-related increases in plasma concentrations of L-692,429 and a half-life of 3.8 +/- 0.2 (+/- SE) h, a plasma clearance of 214 +/- 67 mL/min, and a steady state volume of distribution of 14.2 +/- 4.8 L. Facial flushing or a warm sensation were reported in 4 subjects, primarily at dose levels of 0.2 mg/kg L-692,429 or more, but no other clinical or laboratory adverse experiences appeared related to drug treatment. L-692,429, synthesized as a specific nonpeptide mimic of GH-releasing peptide-6, is thus a well tolerated, highly effective, and selective GH secretagogue in man.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8077339     DOI: 10.1210/jcem.77.5.8077339

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  The Safety and Efficacy of Growth Hormone Secretagogues.

Authors:  John T Sigalos; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-04-08

2.  Synthetic growth hormone secretagogues control growth hormone secretion in the chicken at pituitary and hypothalamic levels.

Authors:  K L Geris; G J Hickey; A Vanderghote; E R Kühn; V M Darras
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.

Authors:  E Arvat; B Maccagno; J Ramunni; L Gianotti; L Di Vito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

Review 4.  Growth hormone secretagogues. Clinical experience and therapeutic potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

5.  Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

Authors:  A A Patchett; R P Nargund; J R Tata; M H Chen; K J Barakat; D B Johnston; K Cheng; W W Chan; B Butler; G Hickey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.